702 King Farm Blvd., Suite 200,
Rockville , MD, 20850
Rockville , MD, 20850
Summary
The fund seeks capital appreciation by investing in small-and-mid-size companies in the United States.
The investment process is designed to highlight companies that are involved in the biotechnology industry.
The process also includes companies involved in research and development, genetic or other biological engineering, and in the design, manufacture, or sale of related biotechnology products or services.
Then More
Link
Directors
Jun 13, 2023- Randall C. Barnes
- Sandra G. Sponem
- Ronald E. Toupin, Jr.
- Angela Brock-Kyle
- Thomas F. Lydon Jr.
- Amy J. Lee
- Ronald A. Nyberg
Chief Compliance Officer
- Elisabeth Miller
Fund Manager(s)
- Michael Byrum
- Ryan Harder
Price
- 52-Week High/Low
- $68.27 - $51.27
- Turnover
- 100%
- Expense Ratio
- 1.64%
Company Name |
Holding |
| AbbVie Inc | 8.19 % |
| Amgen Inc | 6.18 % |
| Gilead Sciences Inc | 4.41 % |
| Regeneron Pharmaceuticals Inc | 4.19 % |
| Vertex Pharmaceuticals Inc | 4.01 % |
| Alnylam Pharmaceuticals Inc | 3.15 % |
| Corteva Inc | 2.9 % |
| Biogen Inc | 2.66 % |
| Moderna Inc | 2.65 % |
| AstraZeneca PLC | 2.58 % |
| More | 2.58 % |
Documents
Performance
YTD
-4.9%
3 Year
-26.03%
5 Year
-6.32%
Best
95.05%
1999
Worst
-45.74%
2002
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | 0.7% | -2.2% | -9.9% | -1.6% | -14.7% | 18.4% | -0.2% | 12.3% | -22.5% | 13.8% |
| Q2 | -5.4% | - | -10.3% | 10% | 28.2% | -3.9% | 8.6% | 7.7% | 0.9% | 7.5% |
| Q3 | - | -3.9% | -2.2% | -21.8% | -7.4% | -9% | 7.1% | 8.4% | 13.2% | -19.5% |
| Q4 | - | 14% | 8.1% | -2.7% | 10.7% | 14% | -18.1% | -2.8% | -9.2% | 10% |
| J | F | M | A | M | J | J | A | S | O | N | D | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -1.3% | 2.2% | -0.1% | -5.6% | - | - | - | - | - | - | - | - |
| 2023 | 2.2% | -4.5% | 0.1% | 1.8% | -2.6% | 0.9% | 0.9% | -0.5% | -4.3% | -6.1% | 6.2% | 13% |
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -5% | 6% | -15% | -18% | 12% | 19% | -9% | 29% | -20% | 8% |
Alpha
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| RYOAX | -5% | 6% | -15% | -18% | 12% | 19% | -9% | 29% | -20% | 8% |
| S&P 500 | - | - | -21% | 27% | 16% | 29% | -6% | 19% | 10% | -1% |
| Alpha | -5% | 6% | 7% | -45% | -4% | -10% | -3% | 10% | -29% | 9% |